Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Numbers...
I'm interested in getting your "feelings" as to what you think IPCI's market cap / share price should be right now and what you see for IPCI going forward and possibly a progression timeline.
Rexista could possibly strike a death blow to Oxycontin
I wanted to write this post for several days now, but did not want to write it without the link to a very important article I had read, which is the basis of the following assumptions.
Well, I have just re-found the article and I think it's well worth reading.
http://www.latimes.com/projects/oxycontin-part1/
I'm not saying these are facts, nor probabilities... but I do think they are very high possibilities, and they make some pieces of the puzzle fit and make the picture make sense.
The condensed version of the article is basically that Oxycontin sells itself as a 2x day drug and gets premium coverage for being an extended release drug... however for many people it does not offer 12 hours of relief BUT if doctors prescribed oxycontin as 3 or 4 x a day... it would lose insurance coverage as a premium drug, so doctors are instead told to offer stronger dosages rather than more frequent doses... and there in lies the overdose issue.
When many doctors began prescribing OxyContin at shorter intervals in the late 1990s, Purdue executives mobilized hundreds of sales reps to “refocus” physicians on 12-hour dosing. Anything shorter “needs to be nipped in the bud. NOW!!” one manager wrote to her staff.
Purdue tells doctors to prescribe stronger doses, not more frequent ones, when patients complain that OxyContin doesn’t last 12 hours. That approach creates risks of its own. Research shows that the more potent the dose of an opioid such as OxyContin, the greater the possibility of overdose and death.
More than half of long-term OxyContin users are on doses that public health officials consider dangerously high, according to an analysis of nationwide prescription data conducted for The Times.
In case anyone else is not clear on the Rexista Fast Track designation, here is an exchange between myself and Della Penna.
I am aware that Rexista with PODRAS has fast track designation - but I'm a little unclear if Rexista PODDS which you will be filing an NDA for soon has been granted fast track designation by the FDA.
Angelo, thanks for your email. You are correct, it is unclear. PODRAS has Fast Track status, but we believe what we are filing in August will have “Priority” status, similar to what Collegium, Elite and Pain T. received given the ADF properties and the need to address the opioid epidemic. If they granted the other’s priority status, they should grant same to us … especially given we have zero Food Effect which the others can’t claim!
Hello Doog,
Was just thinking exactly the same thing... I presented here a factual case where a product inferior to and at an earlier stage than Rexista was valued at $430 million with 20% royalties and all you get here is nickle and dimers.
You're probably aware that as soon as this hits $3.00 to $6.00 most of these "investors" will be out the door... so we may be the only ones meeting in Vegas.
The hardest part I see going forward is to resist temptation to sell at every little pop.
Back in mid 2011 I bought ANIK for around $5.00. It was one of my 10 bagger picks... 1/2 a year later... due to margin calls, I had to sell it at $10.00 - fast forward 2 years later it hit $50.00
I could tell you a few more stories like that... but I'm just tired of trying to make the blind see.
Generic Drug Approvals Hit New Record in 2015
Here's a bit of good news... They expect/hope to be all caught up by end of 2017 so we should be expecting 6 ANDA approvals within the next year-and-half.
More than 700 generic drugs were approved and tentatively approved in 2015, which was the highest figure ever; and in December, FDA granted the highest number of approvals and tentative approvals in a single month (99)
FDA acknowledges that as of 1 October 2012, the backlog included 2,866 ANDAs
But since then, and after a major restructuring of OGD and the hiring of hundreds of new employees, FDA completed first actions on 84% of ANDAs and 88% of PASs by 31 December 2015.
WHOOOOAAAHH - I FOUND IT!!!
http://www.in-pharmatechnologist.com/Ingredients/Pain-Therapeutics-and-King-Pharma-enter-opioid-alliance
A MUST READ FOR EVERYONE TO REALIZE IPCI's POTENTIAL.
My memory served me pretty well - BUT... it's even better than I remembered.
I thought that Pfizer/King paid Pain 20% from which Pain would kick back 9.1% to Durect, but that's not the case - King/Pfizer pays Pain 20% (after $1 billion Sales) PLUS... it pays the Durect 9.1% royalty - that's a total of 30% royalty for a drug that needed 100's millions $ more spent on it, and years of time - Rexista is "ready to go", so what is Rexista worth???
$150 million up front payment
$150 million regulatory development milestones
$ 15 million acceptance of filing
$ 15 million FDA approval
$100 million in research to be spent to develop it
$430 MILLION TOTAL - IN CASH - PLUS 15% royalties on SALES for first $ billion and 20% thereafter.
Based on the reality of the #s in that CONSUMMATED deal, my numbers are FAR from pie in the sky, but very close to the reality of what should happen.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=123776072
http://finance.yahoo.com/news/pfizer-walks-remoxy-end-ulterior-170000862.html
re: Remoxy - As of their last update earlier in 2014, Pfizer was still guiding to re-file the NDA around the middle of 2015. Today's news is a big disappointment. We had previously stated that REMOXY had potential peak sales in the $1.5 billion range. Durect's tiered royalty – roughly 9.1% at $1.5 billion in sales – would have provided significant cash flow to the company.
I'm going by memory so I may be off in my figures... but it's to give a better understanding of what exactly IPCI's potential is.
Note that royalty payments to Durect is almost 10% of SALES or an estimated $150 Million a year in PURE PROFIT.
Also note that Durect's deal is not with Pfizer but with Pain Therapeutics - who bought the rights to Remoxy from Durect for around $20 million??? + 9.1% which a few years later,.. after bringing it along a little further, Pain Therap. sold it to King pharma for I believe $400 million, + I think 20% royalty... and Pfizer bought out King primarily to get Remoxy... and then spent hundreds of millions more to bring it along, and eventually dropped it.
You all need to open your eyes wide and realize what exactly IPCI is about - sure it's a buck and a half NOW, but that doesn't mean that's what it's worth, and good investing is finding a bargain and going all in before everyone else discovers it.
For the umpteenth time - 20K shares today makes you a millionaire in 3 to 5 years.
WAKE THE HELL UP!!!!!!!!!!
http://www.investopedia.com/articles/stocks/06/biotechvaluation.asp?ad=dirN&qo=investopediaSiteSearch&qsrc=0&o=40186
The above link is full of info if you're not familiar with how the pie is split between partners.
If IPCI chooses to manufacture, which I'm sure it will, it will do so on a cost + basis... not at all uncommon in these type of partnerships.
You get estimates on what Rexista will cost to produce when scaled up, and add 20% to that - because everyone is allowed to make a profit - so if cost is $1.00 a pill, then IPCI sells it to it's partner for $1.20.
Doog... where are you... have you seen this... a major piece of news to share with your "friend"
http://finance.yahoo.com/news/fda-issues-complete-response-letter-210707350.html
NORTHVALE, N.J., July 15, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP) today announced that the U.S. Food and Drug Administration (the “FDA”) has issued a Complete Response Letter (the “CRL”) regarding the New Drug Application (the “NDA”) for SequestOx™
This is the reason I would like IPCI to partner BEFORE the application even if the deal means a lesser up front payment.
Would feel more confortable if I knew a major pharma was holding IPCI's hand and seeing that all the i's are dotted and the t's are crossed.
Although I think that any major pharma ready to sign on the dotted line would want an involvement in the filing... just to make sure.
http://www.investopedia.com/terms/n/new-drug-application-nda.asp?ad=dirN&qo=investopediaSiteSearch&qsrc=0&o=40186
Once a company reaches the NDA stage, the probability of the drug receiving FDA approval and being marketed in the U.S. exceeds 80%. Filing of an NDA typically does not result in a substantial increase in the share price of the sponsor company, as most of the stock appreciation is likely to have occurred as the investigational drug progressed through successive phases of earlier clinical trials.
Say what???
We haven't yet received our pie "with ice cream on top"... but I expect that to change soon - and expect several days of $1.00 plus pps increases as this needle in the haystack is found - every mutual fund that comes in looking to pick up a million shares will drive the price up $1.00 - 10 funds = $10 Plus.
It's really very dependent on who the partner will be - and what the deal will be... If there are more than one suitor... we will get fair value... which I expect to be considerable.
I'm hoping it will be Pfizer and see it as a first step of a takeover to protect their Lyrica franchise... a wild but not unreasonable guess... takeover at $3 to $4 billion in end of 2018.
http://www.investopedia.com/terms/n/new-drug-application-nda.asp?ad=dirN&qo=investopediaSiteSearch&qsrc=0&o=40186
DEFINITION of 'New Drug Application (NDA)'
The final step formally taken by a drug sponsor, wherein it applies to the Food and Drug Administration (FDA) for the approval required to market a new drug in the U.S. An NDA is a comprehensive document with 15 sections that includes data and analyses on animal and human studies, the drug’s pharmacology, toxicology and dosage, and the process to manufacture it. When an NDA is submitted, the FDA has 60 days to decide whether to file it for review, or reject it because some required information is missing. The goal of the FDA’s Center for Drug Evaluation and Research (CDER) is to review and act on at least 90% of NDAs for standard drugs within 10 months after the applications are received, and six months for priority drugs.
PDUFA date is set at 6 months from the date RECEIVED, not accepted - so if filed by mid August then PDUFA date by mid February... I'm fairly certain it was also granted priority review... as PODRAS was.
if IPCI goes into manufacturing of Rexista as Angelo has asserted. Was hoping he'd point to where he got that info.
It would appear from the statement below, that along with Focalin, 5 other drugs are also partnered with PAR already.
re: the very strong commercial relationship between Par and IPCI I believe has since become an open marriage where Par can manufacture on it's own the drugs partnered with IPCI, likewise IPCI can partner those same drugs with other concerns... including Focalin... although it seems neither has strayed from the relationship re: focalin.
There was a RUMOR a couple years back that Par had offered ~ $8.00 per share, which the Odidi's turned down - RUMOR, not necessarily fact... but that might have soured the relationship some.
http://www.intellipharmaceutics.com/releases.cfm?Year=&ReleasesType=&PageNum=7
August 1, 2007
IntelliPharmaCeutics Announces Equity Investment by Par Pharmaceutical In Separate Agreement, IntelliPharmaCeutics to Collaborate with Par in the Development and Marketing of Controlled Release Generic Drug Products
TORONTO, Aug. 1 /CNW/ - IntelliPharmaCeutics Ltd. today announced that Par Pharmaceutical (NYSE: PRX) has made a significant equity investment in the Company. IntelliPharmaCeutics Ltd., through its operating company, IntelliPharmaCeutics Corp., develops, licenses and markets both new and generic controlled-release pharmaceutical products. Par Pharmaceutical is a major developer and distributor of generic and branded drugs in the U.S. market.
Under the terms of the investment, Par Pharmaceutical will acquire a 4.2% equity interest in IntelliPharmaCeutics, on terms typical for an investment of this sort and magnitude. The funds will be used by IntelliPharmaCeutics Corp. for general corporate and working capital purposes.
IntelliPharmaCeutics Corp. today also announced that it has signed a drug development collaboration with Par Pharmaceutical. Under the arrangement, IntelliPharmaCeutics will apply its proprietary technology to the formulation and development of four generic drug products (ANDA's) which are bioequivalent to significant branded drugs with substantial commercial sales in the United States. The terms of the deal provide that Par will be responsible for certain costs of development, and that IntelliPharmaCeutics will receive substantial milestone, incentive and success-based payments, together with a share of the profits of commercialization. Par will be responsible for the distribution of the drugs in the United States. These four new collaborations bring the total of drugs under development with Par to six, and represent the continuation and solidification of a very strong commercial relationship between the companies.
Dr. Isa Odidi, CEO and Co-Chief Scientific Officer of IntelliPharmaCeutics, expressed his deep satisfaction with the expanding relationship: "We are very pleased that Par believes enough in the present value and future prospects of the Company that they are prepared to make an equity investment of this magnitude and we are proud to have such a significant drug developer and distributor as Par as a collaboration partner. We view the completion of these new deals as a strong endorsement of our proprietary technologies, of our ability to apply them to a range of small drug molecules and of our willingness to engage in dynamic, cooperative and productive relationships with our development partners. We are confident that we will be able to leverage these investment proceeds to substantially advance our exciting internal pipeline products. These new products, and the next-level technologies they will utilize, could provide the impetus to propel the Company to the next level."
I posted the following on June 10th and hold to these numbers.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=123230322
I think what is far more important than the filing is the FDA acceptance of the NDA which is usually within 30 days after filing, and issuance at that time the PDUFA date... which should be for 6 months from date of filing since they are fast-tracked.
Acceptance of the NDA pretty much cements that they do NOT indeed need to do a phase 3 - which saves about 20 million $, and even more importantly around 2 years of time,
I think once that is known for sure... we'll see a partnership announced that takes all that into consideration.
I believe it will in fact be accepted and I am then expecting a $400 million total package -
$40 million up front + 20% royalty payments ON SALES OR REVENUE
$60 million on FDA approval
$100 million on $1 Billion aggregate sales milestone
$200 million on $3 billion aggregate sales milestone
or possibly 25% to 30% royalty payments on a $250 to $300 million total package. Also believe they will get a "rights of First Refusal" on Rexista w/ PODRAS
Royalty splits vary and depend mostly as to what stage of the approval process the drug is in - preclinical usually pays ~ 5% - if at successful phase 1, then usually ~ 10% - successful phase 2 can net you 12% to 15% - a successful phase 3 usually pays 20% - If FDA approved, easily 30% to 50% can be had - in Rexista's case if partnered before approval I would say 20% is conservative. Royalty payments are based on sales or revenues... not profits... so if IPCI negotiates 20% royalties it will be 20% of sales and the full payment is all profit to them... like the Focalin payments.
Rolling out a drug is very expensive and usually an agreed amount... say $30 million first year - 15 million 2nd year is set aside before royalties are paid... but long term profit margins on drugs - especially pills like Rexista are very high - my guess 65% to 80% profit margin - but, the royalty payments will be on sales or revenues, NOT profits.
Additionally... part of the approval process is that IPCI needs to have in place, proof that it can produce commercial quantities of Rexista utilizing current Good Manufacturing Process cGMP.
IPCI has always maintained that it intends to manufacture Rexista to assure trade secrets are not disclosed, so my guess is they will need around $20 million to set that up... I expect that will come from the partner as milestone payment once the deal is signed, I would also expect partner will want possibly 5 million shares at market cost... so any figures should reflect ~ 40 Million shares FULLY DILUTED.
their other products filed for approval has been sitting for years? FDA approval is supposed to be 10 months.
Epizyme nabs combo trial deal with Genentech for NHL candidate
Financial details of the deal were undisclosed.
my understanding was that you were holding 46K shares.
Have you sold them and are you short now??
State your position... CLEARLY
Actually their fiscal year ends November 30... so even June would be considered 3rd quarter
Best forget which quarter and go by June/July timeframe.
I think what is far more important than the filing is the FDA acceptance of the NDA which is usually within 30 days after filing, and issuance at that time the PDUFA date... which should be for 6 months from date of filing since they are fast-tracked.
Acceptance of the NDA pretty much cements that they do NOT indeed need to do a phase 3 - which saves about 20 million $, and even more importantly around 2 years of time,
I think once that is known for sure... we'll see a partnership announced that takes all that into consideration.
I believe it will in fact be accepted and I am then expecting a $400 million total package -
$40 million up front + 20% royalty payments
$60 million on FDA approval
$100 million on $1 Billion aggregate sales milestone
$200 million on $3 billion aggregate sales milestone
or possibly 25% to 30% royalty payments on a $250 to $300 million total package.
Pfizer opioid given mixed report after posing a ‘quandary’ for FDA panel
http://www.fiercebiotech.com/biotech/pfizer-s-opioid-given-mixed-report-after-posing-a-quandary-for-fda-panel?mkt_tok=eyJpIjoiWVRnM1ltWmlOR1kyWVRBeSIsInQiOiJGYUdObGlBT0VMbk50RFpFQ2k4Ync0ckNxOFJWdzZVVWQrcFV4NjdLdlRpRnNtaGFXTkdOeHppUzBlYlRBM2dDTUZWYnNCcVd0WGhHSXpZNEJoN2hBUng4QzFYV29Ba0k2VDZlM2k1K0szZz0ifQ%3D%3D&mrkid=630788&utm_medium=nl&utm_source=internal
I'm on record for $50 a share - within 3 to 5 years - now within 3 years.
Again!!! 20,000 SHARES TODAY MAKES YOU A MILLIONAIRE IN 3 YEARS!!!
With me it was never about the generics - always been about Rexista and Regabatin... not that the generics are feeble in themselves, but they pale in comparison to the NDAs.
The IPCI platform is worth BILLIONS.
There must Be a reason why he doesn't buy More!
Do you hate lying FUDsters as much as I do???
here are facts: they raised $397,244 by selling 193,043 shares - they averaged $2.06 so I guess it was them with all that available stock on the ask - and they raised $122,092 by converting 58,139 warrants, so the warrants had an exercise cost of $2.10.
193,043 + 58,139 = 251,182 shares = 1% dilution. - very frugal as always.
All previous sales on the ATM have been at around $3.25 and IPCI has always been very stringent about diluting so why did they not sell ATM when it popped to over $3.00... why sell at an average of $2.06???
Here's my opinion: My guess is that they are working on a partnership that may pop it well above $3.00, and includes a sizeable up front payment, but it's not getting done in a timely manner, and therefore... the last minute sales at 2.06.
But Woodcock also said that the agency sifted through the ANDA backlog and identified all of the first generics, or applications which offer a first wave of competition to their brand name counterparts, and that none of the applications left in the backlog are for such drugs.
It appears the FDA is more interested in granting approval on the First Filers so that there is competition and a price drop all around - as to the johnny come lately, I think they are not as concerned about... at least I don't think they are a priority.
So I think that possibly any day between now and November approval will be granted to Handa for all strengths except conditional approval on the 400 mg, and Approval to Ipci for the 400 mg and conditional approval on all other strengths.
I don't necessarily believe that all other companies will at that time be issued conditional approval - I hope
Anyone know if the patent application is for US only or other Worldwide markets - all of Europe perhaps, Canada?
Buongiorno fabius
Regarding the $10 Billion figure - doog read it right - without doing any serious research I simply gave each of the 20 opiate drug candidates $500 million value each, keeping in mind that whatever excess I might have given it would easily be made up for by utilizing the platform for sleeping pills and anti-psychotic drugs.
Starting to do some research and came across this
http://www.drugs.com/news/fatal-overdoses-rising-sedatives-like-valium-xanax-60198.html
don't have any figures but sleeping pills are probably also excellent candidates for the PODRAS platform.
There are many here with far greater aptitude for research than me, dtstx, doog, InTheTrenches, muddy, hint hint perhaps they can give a hand with what the total market is for anti-psychotics, sedatives, sleeping pills, opiates and what ever else Podras can be incorporated into.
Handa believes it is the first applicant to file an ANDA containing a paragraph IV certification for the 50 mg, 150 mg, 200 mg and 300 mg strengths of the product, which would potentially provide 180 days of marketing exclusivity. According to IMS Health data, annual U.S. sales for these strengths of Seroquel XR® are approximately $808 million. The ANDA also includes a 400 mg dosage strength.
http://www.in-pharmatechnologist.com/Drug-Delivery/James-bond-like-tech-is-the-end-to-overdoses-says-formulation-firm
From the article above (thanxs Doog) everyone should read it, pay particular attention to the topic "Licensing Deals"
Sept. 2014 - Isa Odidi CEO of IPCI says he has found the "holy Grail" of drug delivery formulations.
March 2016 - According to Haddox, (Perdue VP) the "holy grail" for the pharmaceutical industry is an opioid that delivers relief for patients while preventing abuse by ingestion.
Sept 2014 - Odidi envisaged licensing the formulation to many companies on an "as-needed basis". But "some companies might get exclusivity depending on how much they pay for it" he added.
Feb 2016 - Jessica Merrill
?@Jessicaemerrill Just talked to Purdue CEO Mark Timney at BIO CEO, who says 2016 is the year for transformational M&A.
And then there was this tweet by Luke Timmerman:
Luke Timmerman ?@ldtimmerman · 3h3 hours ago
Mark Timney of Purdue Pharma pushing to raise profile of private co, says he's looking to buy a platform, something transformative #BIOCEO16
Anybody else thinking that maybe Perdue is readying to pay a Billion $ for PODRAS exclusivity on one drug ??? I don't think they can afford the 10 Billion $ for the the whole platform outright.
July 31, 2012
Intellipharmaceutics Settles Patent Litigation With AstraZeneca Concerning Generic Seroquel XR(R)
TORONTO, July 31, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it had reached an agreement with AstraZeneca to settle all outstanding patent litigation concerning its abbreviated new drug application ("ANDA") for the commercialization in the United States of a generic version of the AstraZeneca drug product, Seroquel XR® (quetiapine fumarate extended-release) tablets.
On July 30, 2012, and pursuant to the settlement, AstraZeneca and the Company filed proposed Consent Judgments in the District Court for the Southern District of New York to conclude the litigation, subject to other regulatory review. The settlement provides, in part, that the Company is permitted to launch its generic versions of the 50, 150, 200, 300 and 400mg strengths of Seroquel XR®, on November 1, 2016, or earlier in certain circumstances, subject only to prior U.S. Food and Drug Administration ("FDA") approval of the Company's ANDA for those strengths. All other terms of the settlement are confidential. The Company's actual launch may also be subject to a six month statutory delay relating to a prior filer of a generic equivalent of the branded product.
Dr. Isa Odidi, CEO and co-Chief Scientific Officer of the Company stated, "We are pleased to conclude the litigation with AstraZeneca on these terms. The agreement permits us to bring our generic Seroquel XR® product to the market in advance of the expiry of the AstraZeneca patents in November 2017, and removes the ongoing expense and uncertainty inherent in patent litigation." I specifically remember that the previous CFO, at a presentation, said he believed they were first to file on one strenght of this... will be interesting to see what happens with this product.
August 28, 2014
Intellipharmaceutics Augments Its Rexista(TM) Oxycodone Development Program With Novel Overdose Deterrence Technology
TORONTO, Aug. 28, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced an enhancement of its Rexista™ abuse-deterrence technologies with a significant improvement designed to prevent overdose when more pills than prescribed are swallowed intact. Intellipharmaceutics' new platform technology is branded PODRAS™ (Paradoxical OverDose Resistance Activating System).
The PODRAS™ platform technology is covered by patents pending with the U.S. Patent and Trademark office. on August 28, 2014 it's already patent pending, so must have applied before that - I recall a PR specifically re: the patent application but now can't find it - but we know it's before August 28, 2014
"We believe this significant advance in our abuse deterrence technology has the potential to positively differentiate Rexista™ from other abuse-deterrent technologies of which we are aware, and represents an important step toward helping patients manage their pain safely," said Dr. Isa Odidi, Chief Executive Officer of Intellipharmaceutics. "In addition to its use with oxycodone, the new technology is potentially applicable to a wide range of drug products that are intentionally or inadvertently abused and cause harm by overdose to those who ingest them."
Intellipharmaceutics' most advanced application of the PODRAS™ platform to date is to its Rexista™ product candidate (oxycodone hydrochloride extended-release tablet), which is designed to deter abuse by both physical interference and overdose.
Preclinical studies of Rexista™ suggest that, unlike other third-party abuse-deterrent oxycodone products, if more tablets than prescribed are deliberately or inadvertently swallowed, the amount of drug active released over 24 hours may be substantially less than expected, even possibly approaching zero. However, if the prescribed number of pills is swallowed, the drug release should be as expected. Apparently they have pre-clinical confirmation that it works
In January 2013, the United States Food and Drug Administration ("FDA") published a paper titled, Guidance for Industry: Abuse-Deterrent Opioids — Evaluation and Labeling, which cited the need for more efficacious abuse deterrence-technology.
In this draft Guidance, the FDA stated, "Opioid analgesics are often manipulated for purposes of abuse. Most abuse-deterrent technologies developed to date are designed to make product manipulation more difficult or to make abuse of the manipulated product less attractive or rewarding. However, these technologies have not yet proven successful at deterring the most common form of abuse - swallowing a number of intact pills or tablets to achieve a feeling of euphoria."
Dr. Ed Sellers, an internationally recognized clinical pharmacologist and Professor Emeritus, University of Toronto, and President of DL Global Partners commented "The risk of overdose due to taking more opiate analgesic than prescribed is a real one. The lack of delivery technologies to reduce that risk is an unmet public health need. The announced technology is promising. Confirmation of its clinical importance in human clinical studies would be a significant contribution to deterring abuse."
Intellipharmaceutics currently expects to begin a series of clinical trials in Canada and the United States in the coming months to further evaluate Rexista™ incorporating its PODRAS™ platform.
This is total speculation on my part - but their low cash burn says they are either doing nothing re: these pre-clinical trials, or... they already have a partner absorbing the cost of pre-clinical work and a contract ready to sign once patent is granted. - All a guess of course.
The average time it takes to obtain a patent from the patent office at this time is about 32 months
I thought shorting a stock is not forbidden?
Manipulation yes. Shorting is not manipulating
Yes wifisherman, I'm well aware of them - there's little doubt in my mind that IPCI did not go from $3+ to $2 in 2 weeks because investors wanted out... but that it's been forced down by selling from one account to another related account on a never relenting downward push... probably picked up very few loose shares, and instead probably sacrificed more than they gained.
What doesn't make sense to me is how they now expect to accumulate 4 million shares without driving the price to $6.00 to $8.00 in doing so.
The only hope they would have is if they can get the shares directly from IPCI, and I believe that WILL NEVER HAPPEN - I believe the Odidis would lend the company money if necessary for as long as it takes to sign a partnership.
I think the Odidis would have agreed to an issue of maybe 1 million shares for $3.50 - but nothing anywhere near $2.00 nor 4 million shares - and now I believe they would not issue shares to them at any price - the knife cuts both ways.
although all the above is assuming that there actually was an offer for 4 million shares at $2.00 - I'm not sure, but activity sure seems to have followed that logic.
that's the post I remember seeing - thanxs
Are we reading too much in these tea leaves???
You would not sign a deal like this UNTIL patent has been issued, nor would you sign it and make it conditional on patent issuance, you would come to an agreement on terms, cross all the t's, dot all the i's, and be ready to sign on the dotted line as soon as patent is issued.
C'mon patent office - start issuing
This office is made for issuing... and that's just what they'll do... well one of these days this office... is gonna issue one for you. duhh do do duhh do do dughhh
LOL
According to Haddox, the "holy grail" for the pharmaceutical industry is an opioid that delivers relief for patients while preventing abuse by ingestion.
I had noticed that meaningful volume and suppression of share price always started at approx 12:30 pm EST - which suggested that the entity is on the west coast beginning his day at 9:00 a.m. and begin shorting at 9:30 a.m. - yesterday and today the activity started at 11:30 a.m. - which suggests that whoever it is, lives in a region not affected by the daylight saving time - in the US it would be Arizona - but more than likely he/she is in the western part of CANADA - I'm assuming canada does not have daylight saving time??? can anyone affirm that???
According to Haddox, the "holy grail" for the pharmaceutical industry is an opioid that delivers relief for patients while preventing abuse by ingestion.
Looks like you took a photo of the monitor Doog.
Check in your program files for a little program called "snipping tool" - it's bundled as part of windows 7 like notepad.
It lets you capture any segment of the monitor and save it as a jpeg - really easy to use and tremendously useful tool.
He probably has the chart set for "near the money" view instead of "see all"
Suddenly having sold 110,000 shares at an average of $8.00 seems brilliant - although they were necessary sales due to margin calls.
Sure glad I bet on the other horse as it was considerably a safer bet... with as much potential as nwbo.
Now it seems like all the bad news is out on the other horse and it's beginning to come on with nothing but potentially great news ahead of it.
It may allow me to re-accumulate my 190K shares on the cheap - got 15K today.
I believe they actually believed during the last raise that it was a bridge raise and they would be raising at a higher price going forward - but who has not underestimated the time it takes to get something done when dealing with the FDA??? A PR stating they are resuming screening would easily take it to $4.00.
BUT, I am really pissed that they did not do the raise with NW - what is going on here - is LP and NW in a tit for tat here??? I can't believe NW was offered these terms and refused them - they need to show unity or they are cutting off their nose to spite their face!!!